Goldman Sachs

Public sector euro benchmark supply is set to restart after a lull last week, with a eurozone sovereign and a French agency hitting screens on Monday for pricing on Tuesday.

Hua Medicine, the third biotechnology firm to list in Hong Kong, got across the finish line with an undersubscribed retail book, even though several blue-chip funds threw their weight behind the deal.

Nio’s IPO on the New York Stock Exchange is set to escape the rout in emerging market stocks mostly unscathed, with its $1.3bn float covered ahead of pricing on Tuesday.

Haidilao International Holding, the Chinese hotpot chain, has covered its HK$7.6bn ($962.6m) IPO in Hong Kong thanks to a stellar line-up of cornerstone investors, said bankers leading the trade.

Qutoutiao and 111 have launched their respective IPOs on the Nasdaq this week, while Liulishuo has headed to New York for a listing.

After a drought of new investment grade corporate bonds from the telecom sector, French operator Orange made it two in two days after Telefónica sold a seven year trade on Tuesday. Orange offered a 12 year tranche as well as another seven year offering, but had to leave something on the table to achieve a €2bn print.

Larsen & Toubro has raked in Rp18.5bn ($256.5m) after selling a block of shares in subsidiary L&T Infotech, finding strong demand from both institutions and retail investors.

Italian gas distributor 2i Rete Gas has dared to test the corporate bond market’s appetite for issuers from the country with a seven year trade. With its government budget on the horizon, some market participants said this deal could make or break the market for Italian issuance in 2018.

Meituan Dianping, one of China’s hottest technology unicorns, has launched bookbuilding for its up to HK$34.6bn ($4.4bn) Hong Kong IPO.

Larsen & Toubro is looking to raise at least Rp18bn ($254.2m) from the sale of stock in its subsidiary Larsen & Toubro Infotech.

LAIX, which runs English teaching app Liulishuo, is planning to float on the New York Stock Exchange for up to $100m.

Biotechnology firm Hua Medicine has launched bookbuilding for its Hong Kong IPO, targeting up to HK$972.1m ($123.9m) in proceeds.